Medtronic Activa
This article was originally published in The Gray Sheet
Executive Summary
Latest iterations of the deep brain stimulation implant for treatment of movement disorders, set for U.S. debut in June, include the Activa RC rechargeable system and Activa PC primary cell non-rechargeable device, both of which incorporate advanced programming and therapy monitoring functions, Medtronic announces May 21. The "next-generation" devices, which provide bi-lateral brain stimulation and treat symptoms of advanced Parkinson's disease and essential tremor, were recently approved via PMA supplement and are the "smallest available," the firm claims. The Activa PC in particular is 20% smaller than previous versions with "similar battery life." The first Activa system was approved in the U.S. in 1997 for treatment of essential and Parkinson's tremor
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.